Myopia
Recent clinical, regulatory, research and industry developments relating to this disease.
Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY): A Randomized, Double-Blind Study to Demonstrate the Efficacy and Safety of Eye Drop Formulations (Atropine Sulphate 0.025 % w/v Eye Drops vs Placebo) in the Management of Controlling Progression of Myopia in Children.
- Q4 2027A Phase III, Randomized, Double-blind, Multiple Doses, Placebo-controlled, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Atropine for the Treatment of Myopia Progression in Children and Adolescents (MODERATO Study)
- Q2 2028Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial
- Q4 2028A Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in Children
Clinical MilestonesViewHide
- 2026-07-02Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical TrialResults expected Q2 2028
- 2026-06-26A Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in ChildrenResults expected Q4 2028
- 2026-02-11A Phase III, Randomized, Double-blind, Multiple Doses, Placebo-controlled, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Atropine for the Treatment of Myopia Progression in Children and Adolescents (MODERATO Study)Results expected Q4 2027
- 2026-01-09Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY): A Randomized, Double-Blind Study to Demonstrate the Efficacy and Safety of Eye Drop Formulations (Atropine Sulphate 0.025 % w/v Eye Drops vs Placebo) in the Management of Controlling Progression of Myopia in Children.Results expected Q3 2027
- 2026-05-22A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic MyopiaCompleted
- 2026-05-22Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression: A Randomized Controlled TrialCompleted
- 2026-01-30A Randomized Controlled Study of Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High MyopiaCompleted
- 2026-07-02ClinicalDelaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical TrialResults expected Q2 2028
- 2026-06-26ClinicalA Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in ChildrenResults expected Q4 2028
- 2026-05-22ClinicalA Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic MyopiaCompleted
- 2026-05-22ClinicalEfficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression: A Randomized Controlled TrialCompleted
- 2026-02-11ClinicalA Phase III, Randomized, Double-blind, Multiple Doses, Placebo-controlled, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Atropine for the Treatment of Myopia Progression in Children and Adolescents (MODERATO Study)Results expected Q4 2027
- 2026-01-30ClinicalA Randomized Controlled Study of Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High MyopiaCompleted
- 2026-01-09ClinicalAtropine in the Treatment of Myopia Study in Malaysia (ATOM-MY): A Randomized, Double-Blind Study to Demonstrate the Efficacy and Safety of Eye Drop Formulations (Atropine Sulphate 0.025 % w/v Eye Drops vs Placebo) in the Management of Controlling Progression of Myopia in Children.Results expected Q3 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Ryjunea is indicated for slowing the progression of myopia in paediatric patients. Treatm… (2025)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Cataract1
- Contact Lenses, Hydrophilic1
- Dementia1
- Epidemiologic Studies1
- Hypoxia1
- Keratomileusis, Laser In Situ1
- Photorefractive Keratectomy1
- Signal Transduction1
Leading journals5
- Investigative ophthalmology & visual science2
- BMC ophthalmology1
- JAMA network open1
- Optometry and vision science : official publication of the American Academy of Optometry1
- Proceedings of the National Academy of Sciences of the United States of America1
Leading researchers8
- Andrews SJ1
- Brenowitz WD1
- Buto PT1
- Casaletto K1
- Chamberlain P1
- Chen W1
- Choquet H1
- Deng L1
Affiliations (unnormalised)6
- Aarhus University Hospital1
- Boston University1
- Brien Holden Vision Institute and School of Optometry and Vision Science1
- Centre for Eye Research Australia; Ophthalmology1
- Centre for Ocular Research and Education1
- Children's University Hospital1
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Myopia is a refractive error in which incoming parallel light is focused in front of the retina when accommodation is relaxed. It is also called nearsightedness and is commonly classified in research as myopia, secondary myopia, axial myopia, or refractive myopia. The literature also distinguishes low and high myopia, and defines pre-myopia as a state relevant to prevention research.
Myopia can result from an overly curved cornea or from an eyeball that is too long from front to back. The reviewed literature also indicates that both genetic and environmental factors contribute to its development and rising prevalence. Secondary myopia is recognized as a distinct descriptive category in research classifications.
The core mechanism is an optical mismatch that places the focal point anterior to the retina rather than on it. This is associated with altered ocular refraction, including axial elongation or increased corneal curvature. The literature on myopia also centers on visual acuity and ocular refraction as key biological and clinical features.
Early onset in children is associated with greater risk of later complications, including progression to high myopia and myopic macular degeneration. The epidemiology literature identifies both genetic and environmental factors as contributors to risk. School-age children are a major focus of risk research because of the high prevalence and progression observed in this group.
AI-generated summary grounded in MeSH and 2 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A refractive error in which rays of light entering the EYE parallel to the optic axis are brought to a focus in front of the RETINA when accommodation (ACCOMMODATION, OCULAR) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.